7 Penny Stocks For Your Watch List This Week If You Like Biotech In July
Looking for biotech penny stocks to watch right now? Here are 7 for your list this week.
The post 7 Penny Stocks For Your Watch List This Week If You Like Biotech In July appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock…
Current & Former Biotech Penny Stocks To Watch This Week
Is the stock market going to crash? What are the best penny stocks to buy right now? Will July bring new highs in the stock market in 2021? These are just a few of the many questions being asked as we embark on the second half of the year. With firm trends in place, there’s definitely a lot of moving parts to account for. Not only is this the first week of Q3, but it’s also the first week of the second half of the year. With that, we’ve seen the first round of earnings suggest economic strength in the post-pandemic recovery. We’ve also gained some additional insight from the Fed regarding its stance on inflation – which remains “transitory” and not a major concern (for now).
We’ve also seen the meme stock mayhem continue pushing shares of companies like AMC Entertainment (NYSE: AMC), GameStop (NYSE: GME), and plenty of others in different directions. This new type of activist investing has given retail traders a voice. Now we not only see top Wall Street analysts giving their 2 cents on the state of the markets, but YouTubers are also becoming mainstay contributors to financial media outlets.
The week ahead may be short, but there is plenty to keep track of. Today we’ll look at one of the more volatile parts of the market, biotech. You can see things like phase data or even rumors of patents spark big moves in certain stocks. This list of penny stocks (and former penny stocks) will focus on companies with recent or upcoming events that could be good to keep in mind as “H2” kicks off on July 6th.
Former Penny Stocks To Watch #1: GT Biopharma Inc. (NASDAQ: GTBP)
GT Biopharma has been one of the biotech penny stocks we’ve discussed many times in the past. In fact, among many of the big movers this year, GTBP stock stacks up against many of the cohorts of the group. Less than 6 months ago, shares were trading below $5, and recently the former penny stock reached highs of $19.73 in June. What’s been a driving force behind the momentum?
There’ve been a few key events that have helped spark attention from the market. The foremost has been the company’s progress with its immunotherapy treatment pipeline. The company’s lead treatment candidate, GTB-3550, is undergoing clinical trials in a Phase 1/2 study in patients with acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (HR MDS). Late last month, the company presented interim data on GTB-3550 at the Raymond James Human Health Innovation Conference.
Anthony Cataldo, GT Biopharma Chairman and Chief Executive Officer, explained, “We have seen significant reductions in CD33+ cancer cells in four of the last seven patients (57%) treated with doses of GTB-3550 ranging from 25mcg/kg/day to 150mcg/kg/day. This early sign of CD33+ target-specific cancer cell killing is very encouraging as we begin to focus on transitioning to the expanded efficacy part of the current GTB-3550 clinical trial.”
Recent Developments To Watch With GTBP Stock
Along with GTB-3550, the company has several other treatment candidates in its pipeline to target breast, lung, gastric, colorectal, and ovarian cancer indications. These indications include ones that express HER2 (GTB-6550), PD-L1 (GTB-4550), and B7H3 (GTB-5550). Last week Anthony Cataldo presented as a VIP speaker at Sir Anthony Ritossa’s Global Family Office Investment Summit in Monaco. Given that analysts have already given a bullish stance on the company, details from last week’s presentation could be of interest heading into the new month. What’s more, some of the analysts covering the company have already begun boosting targets.
B. Riley, for instance, discussed how NK cell therapy combined with GT’s TriKE showed “synergy” in preclinical prostate cancer. Below, the image shows GT Biopharma’s GTB-5550 TriKE combined with Fate Therapeutics’ FT538 iNK cells.
The combination showed significant results compared to 3 other models on a 72-hour timeline. B. Riley lifted its $21 to $26 at the end of June.
2. Ocugen Inc. (NASDAQ: OCGN)
Ocugen is another former penny stock that has gained in popularity over the last few months. Initially, the company was the center of attention thanks to its pipeline treatments for wet-AMD last year. However, the larger spark came when Ocugen pivoted into the coronavirus arena. Its co-development deal in December with Bharat Biotech ignited more excitement in the stock.
Fast-forward a few months, and now OCGN stock is in the same conversations as Pfizer (NYSE: PFE), Moderna (NASDAQ: MRNA), and Johnson & Johnson (NYSE: JNJ). In particular, OCGN stock could be on the radar this week after a late-breaking development just before the holiday weekend.
Recent Developments To Watch With OCGN Stock
On July 2nd, Ocugen reported new evidence from Bharat Biotech. The company shared positive results of its Phase 3 study of COVAXIN; a whole virion inactivated COVID-19 vaccine candidate. According to the company, it demonstrated a vaccine efficacy in mild, moderate, and severe COVID-19 disease of 77.8% with efficacy against severe COVID-19 disease alone of 93.4%.
“With the Delta variant becoming a dominant strain of COVID-19 in the United States, we believe that the Phase 3 efficacy results reported by Bharat Biotech demonstrate that COVAXIN has the potential to become an important option to expand protection against this emerging variant. Combining these data with the only Delta-variant results from a controlled Phase 3 clinical trial, evidence continues to support a favorable benefit-risk profile for COVAXIN.”
Dr. Bruce Forrest, Acting Chief Medical Officer and a member of the vaccine scientific advisory board of Ocugen.
Penny Stocks To Watch #1: Odonate Therapeutics Inc. (NASDAQ: ODT)
Now, getting to the current penny stocks to watch, Odonate Therapeutics could be another name to keep in mind. The company isn’t the most vocal when it comes to headlines. But that hasn’t stopped traders from focusing on core developments being made by the company. In particular, things are up in the air when it comes to the future of the company. This has remained a source of speculation in the market, contributing to several volatility spikes along the way.
Earlier this year, the company announced the discontinuation of the development of its tesetaxel treatment and its intent to wind down tesetaxel-related operations. Teseteaxel is a type of chemotherapy agent in the “taxanes” class of drugs. These are used in cancer treatment, including those in breast cancer. The company said its clinical data package for tesetaxel is “unlikely to support” FDA approval. But that hasn’t put a complete stop to trading activity in the market.
Recent Developments To Watch With ODT Stock
Whether it has an impact or not, events last week could be something to keep in mind. Friday shares began trading higher after a new filing came out. A 13G filing showed Ikarian Capital has a 5.2% stake in the company. In many cases, when larger firms build sizeable positions in biotech companies, the market takes notice. But again, whether this “event” is a lasting one for ODT stock in July is yet to be seen.
2. Antares Pharma Inc. (NASDAQ: ATRS)
Since the 2020 sell-off early last year, ATRS stock has been on the recovery path. In fact, since last March, shares of Antares Pharma have bounced from lows of $1.60 to highs of over $5 earlier this year. Closing out the week last week, the penny stock sat around $4.50, which continued its 4-day uptrend.
Not only did the company present at the Raymond James Human Health Innovations Conference, but it also filed an Investigational New Drug Application with the FDA for its early-stage study of ATRS-1902. This is the company’s candidate for treating acute adrenal insufficiency, known as adrenal crisis.
Recent Developments To Watch With ATRS Stock
Other updates could also be a point of interest heading into this week. Namely, the company’s update on June 28th that its partner Idorsia Ltd initiated a Phase 3 registration study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia’s P2Y12 receptor antagonist, in suspected acute myocardial infarction utilizing Antares’ Quickshot® auto-injector. Last December, the FDA designated Idorsia’s investigation of selatogrel for this treatment as a “fast-track” development program. What’s more, Idorsia will be responsible for the global commercialization of the product, pending regulatory approvals, and Antares will be entitled to receive royalties on net sales of the commercial product should it reach that stage.
3. ObsEva (NASDAQ: OBSV)
Shares of ObsEva stock have remained relatively flat for the last several months. But this week could be an important one for the company. ObsEva focuses on therapies to improve women’s reproductive health. What’s so important about this week for the company?
Upcoming Developments To Watch With OBSV Stock
This week the company presents clinical data from its PROLONG Phase 2a proof-of-concept study of ebopiprant. This is ObsEva’s oral prostaglandin F2alpha (PGF2α) antagonist for treating spontaneous preterm labor. Data will be presented at the Society for Reproductive Investigation 68th Annual Meeting, held virtually and in Boston on July 7th and July 8th. Both presentations will happen after the market closes on both days, so it could be something to keep in mind if OBSV stock is on your watch list right now.
4. Palatin Technologies Inc. (NYSE: PTN)
Similar to Odonate, Palatin Technologies may be in the spotlight thanks to recent filings coming to light. The company recently announced that it completed an End-of-Phase 2 meeting with the FDA. This was for its PL9643 treatment of dry eye disease (DED). Carl Spana, Ph.D., President and Chief Executive Officer of Palatin, explained that “We now have clarity on the registrational path required to demonstrate the safety and efficacy of PL9643, having reached agreement with FDA on all key elements of PL9643’s pivotal phase 3 program for DED.”
Recent Developments To Watch With PTN Stock
Besides this latest news, a barrage of Form 4s have flooded the filings of PTN stock. Several of the company’s officers and directors purchased shares of stock between average prices of $0.60 and $0.62 at the end of June and the beginning of July. Obviously, when insiders are purchasing shares, it can be looked highly upon by the investing public. In this case, considering the current price is right around the levels insiders bought, this could be something to keep in mind in the week ahead.
5. Seelos Therapeutics Inc. (NASDAQ: SEEL)
Finally, Seelos Therapeutics continues to remain a focus for traders. This comes just a few months after SEEL stock reached highs of $6.60. Since then, shares of the penny stock have plummeted to the current levels they’re trading at right now. But that doesn’t seem to have deterred analysts from getting in on the action.
Seelos has become one of the psychedelic penny stocks to watch this year. At one point, it was the largest holding of the Horizon’s Psychedelic Stock ETF (NEO: PSYK). While the penny stock remains in the top 5 holdings, it has been dethroned by Cybin Inc. (OTC: CLXPF), which holds the top spot right now. Needless to say, recent developments could put a slightly brighter spotlight on the company in July.
Recent Developments To Watch With SEEL Stock
Last week, Guggenheim analyst Yatin Suneja initiated coverage on Seelos Therapeutics. The analyst gave a Buy rating and announced a price target of $8. The company was also recently added to the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes.
Biotech Penny Stocks To Watch This Week
No matter if we’re talking about current or former penny stocks, the focus is the same. Recent and upcoming events could play a part for some or all of these companies in the month ahead. Key pipeline developments, new insider ownership, institutional interest, and more are some of the highlights to keep track of. Heading into the new month, quarter, and half of 2021, it is going to be important to understand potential catalysts at play.
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP) Midam has been paid $150,000 for a period from March 1, 2021, to April 1, 2021. This compensation is payment 1 of 12 as part of a 12-month agreement between Midam Ventures LLC & GT Biopharma (GTBP), for a period from March 1, 2021, to February 28, 2022. Midam Ventures LLC expects to be paid $150,000 per month for a total of 12 months by GT Biopharma (GTBP). Midam has been paid an additional $150,000 for a period from April 2, 2021, to May 1, 2021. This compensation is payment 2 of 12 as part of the Agreement. Midam has been paid an additional $150,000 for a period from May 2, 2021, to June 1, 2021. This compensation is payment 3 of 12 as part of the Agreement. Midam has been paid an additional $150,000 for a period from June 2, 2021, to July 1, 2021. This compensation is payment 4 of 12 as part of the Agreement. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during, or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click Here For Full Disclaimer
It was Jan. 11, 2024 when software giant Microsoft (MSFT) briefly passed Apple (AAPL) as the most valuable company in the world.
Microsoft's stock closed 0.5% higher, giving it a market valuation of $2.859 trillion.
It rose as much as 2% during the session and the company was briefly worth $2.903 trillion. Apple closed 0.3% lower, giving the company a market capitalization of $2.886 trillion.
"It was inevitable that Microsoft would overtake Apple since Microsoft is growing faster and has more to benefit from the generative AI revolution," D.A. Davidson analyst Gil Luria said at the time, according to Reuters.
The two tech titans have jostled for top spot over the years and Microsoft was ahead at last check, with a market cap of $3.085 trillion, compared with Apple's value of $2.684 trillion.
Analysts noted that Apple had been dealing with weakening demand, including for the iPhone, the company’s main source of revenue.
Demand in China, a major market, has slumped as the country's economy makes a slow recovery from the pandemic and competition from Huawei.
Sales in China of Apple's iPhone fell by 24% in the first six weeks of 2024 compared with a year earlier, according to research firm Counterpoint, as the company contended with stiff competition from a resurgent Huawei "while getting squeezed in the middle on aggressive pricing from the likes of OPPO, vivo and Xiaomi," said senior Analyst Mengmeng Zhang.
“Although the iPhone 15 is a great device, it has no significant upgrades from the previous version, so consumers feel fine holding on to the older-generation iPhones for now," he said.
A man scrolling through Netflix on an Apple iPad Pro. Photo by Phil Barker/Future Publishing via Getty Images.
Counterpoint said that the first six weeks of 2023 saw abnormally high numbers with significant unit sales being deferred from December 2022 due to production issues.
Apple is planning to open its eighth store in Shanghai – and its 47th across China – on March 21.
The company also plans to expand its research centre in Shanghai to support all of its product lines and open a new lab in southern tech hub Shenzhen later this year, according to the South China Morning Post.
Meanwhile, over in Europe, Apple announced changes to comply with the European Union's Digital Markets Act (DMA), which went into effect last week, Reuters reported on March 12.
Beginning this spring, software developers operating in Europe will be able to distribute apps to EU customers directly from their own websites instead of through the App Store.
"To reflect the DMA’s changes, users in the EU can install apps from alternative app marketplaces in iOS 17.4 and later," Apple said on its website, referring to the software platform that runs iPhones and iPads.
"Users will be able to download an alternative marketplace app from the marketplace developer’s website," the company said.
Apple has also said it will appeal a $2 billion EU antitrust fine for thwarting competition from Spotify (SPOT) and other music streaming rivals via restrictions on the App Store.
The company's shares have suffered amid all this upheaval, but some analysts still see good things in Apple's future.
Bank of America Securities confirmed its positive stance on Apple, maintaining a buy rating with a steady price target of $225, according to Investing.com.
The firm's analysis highlighted Apple's pricing strategy evolution since the introduction of the first iPhone in 2007, with initial prices set at $499 for the 4GB model and $599 for the 8GB model.
BofA said that Apple has consistently launched new iPhone models, including the Pro/Pro Max versions, to target the premium market.
Analyst says Apple selloff 'overdone'
Concurrently, prices for previous models are typically reduced by about $100 with each new release.
This strategy, coupled with installment plans from Apple and carriers, has contributed to the iPhone's installed base reaching a record 1.2 billion in 2023, the firm said.
Apple has effectively shifted its sales mix toward higher-value units despite experiencing slower unit sales, BofA said.
This trend is expected to persist and could help mitigate potential unit sales weaknesses, particularly in China.
BofA also noted Apple's dominance in the high-end market, maintaining a market share of over 90% in the $1,000 and above price band for the past three years.
The firm also cited the anticipation of a multi-year iPhone cycle propelled by next-generation AI technology, robust services growth, and the potential for margin expansion.
On Monday, Evercore ISI analysts said they believed that the sell-off in the iPhone maker’s shares may be “overdone.”
The firm said that investors' growing preference for AI-focused stocks like Nvidia (NVDA) has led to a reallocation of funds away from Apple.
In addition, Evercore said concerns over weakening demand in China, where Apple may be losing market share in the smartphone segment, have affected investor sentiment.
And then ongoing regulatory issues continue to have an impact on investor confidence in the world's second-biggest company.
“We think the sell-off is rather overdone, while we suspect there is strong valuation support at current levels to down 10%, there are three distinct drivers that could unlock upside on the stock from here – a) Cap allocation, b) AI inferencing, and c) Risk-off/defensive shift," the firm said in a research note.
Major typhoid fever surveillance study in sub-Saharan Africa indicates need for the introduction of typhoid conjugate vaccines in endemic countries
There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high…
There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high burden combined with the threat of typhoid strains resistant to antibiotic treatment calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines (TCVs) in endemic settings along with improvements in access to safe water, sanitation, and hygiene.
Credit: IVI
There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high burden combined with the threat of typhoid strains resistant to antibiotic treatment calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines (TCVs) in endemic settings along with improvements in access to safe water, sanitation, and hygiene.
The findings from this 4-year study, the Severe Typhoid in Africa (SETA) program, offers new typhoid fever burden estimates from six countries: Burkina Faso, Democratic Republic of the Congo (DRC), Ethiopia, Ghana, Madagascar, and Nigeria, with four countries recording more than 100 cases for every 100,000 person-years of observation, which is considered a high burden. The highest incidence of typhoid was found in DRC with 315 cases per 100,000 people while children between 2-14 years of age were shown to be at highest risk across all 25 study sites.
There are an estimated 12.5 to 16.3 million cases of typhoid every year with 140,000 deaths. However, with generic symptoms such as fever, fatigue, and abdominal pain, and the need for blood culture sampling to make a definitive diagnosis, it is difficult for governments to capture the true burden of typhoid in their countries.
“Our goal through SETA was to address these gaps in typhoid disease burden data,” said lead author Dr. Florian Marks, Deputy Director General of the International Vaccine Institute (IVI). “Our estimates indicate that introduction of TCV in endemic settings would go to lengths in protecting communities, especially school-aged children, against this potentially deadly—but preventable—disease.”
In addition to disease incidence, this study also showed that the emergence of antimicrobial resistance (AMR) in Salmonella Typhi, the bacteria that causes typhoid fever, has led to more reliance beyond the traditional first line of antibiotic treatment. If left untreated, severe cases of the disease can lead to intestinal perforation and even death. This suggests that prevention through vaccination may play a critical role in not only protecting against typhoid fever but reducing the spread of drug-resistant strains of the bacteria.
There are two TCVs prequalified by the World Health Organization (WHO) and available through Gavi, the Vaccine Alliance. In February 2024, IVI and SK bioscience announced that a third TCV, SKYTyphoid™, also achieved WHO PQ, paving the way for public procurement and increasing the global supply.
Alongside the SETA disease burden study, IVI has been working with colleagues in three African countries to show the real-world impact of TCV vaccination. These studies include a cluster-randomized trial in Agogo, Ghana and two effectiveness studies following mass vaccination in Kisantu, DRC and Imerintsiatosika, Madagascar.
Dr. Birkneh Tilahun Tadesse, Associate Director General at IVI and Head of the Real-World Evidence Department, explains, “Through these vaccine effectiveness studies, we aim to show the full public health value of TCV in settings that are directly impacted by a high burden of typhoid fever.” He adds, “Our final objective of course is to eliminate typhoid or to at least reduce the burden to low incidence levels, and that’s what we are attempting in Fiji with an island-wide vaccination campaign.”
As more countries in typhoid endemic countries, namely in sub-Saharan Africa and South Asia, consider TCV in national immunization programs, these data will help inform evidence-based policy decisions around typhoid prevention and control.
###
About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.
IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO) and developed a new-generation typhoid conjugate vaccine that is recently pre-qualified by WHO.
IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden, a Country Office in Austria, and Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, and Thailand provide state funding. For more information, please visit https://www.ivi.int.
Incidence of typhoid fever in Burkina Faso, Democratic Republic of the Congo, Ethiopia, Ghana, Madagascar, and Nigeria (the Severe Typhoid in Africa programme): a population-based study
We’ve added 60% to national debt since 2018. Germany - a country with major economic woes - added ‘just’ 32%.
Maybe it will never matter. Maybe MMT is real. Maybe we just cancel or inflate it out. Maybe career real estate borrowers or career politicians aren’t the answer.
I have no idea. Only time will tell. But it’s going to be fascinating to watch it play out.
He is right: it will be fascinating, and the latest budget deficit data simply confirmed that the day of reckoning will come very soon, certainly sooner than the two years that One River's Eric Peters predicted this weekend for the coming "US debt sustainability crisis."
According to the US Treasury, in February, the US collected $271 billion in various tax receipts, and spent $567 billion, more than double what it collected.
The two charts below show the divergence in US tax receipts which have flatlined (on a trailing 6M basis) since the covid pandemic in 2020 (with occasional stimmy-driven surges)...
... and spending which is about 50% higher compared to where it was in 2020.
The end result is that in February, the budget deficit rose to $296.3 billion, up 12.9% from a year prior, and the second highest February deficit on record.
And the punchline: on a cumulative basis, the budget deficit in fiscal 2024 which began on October 1, 2023 is now $828 billion, the second largest cumulative deficit through February on record, surpassed only by the peak covid year of 2021.
But wait there's more: because in a world where the US is spending more than twice what it is collecting, the endgame is clear: debt collapse, and while it won't be tomorrow, or the week after, it is coming... and it's also why the US is now selling $1 trillion in debt every 100 days just to keep operating (and absorbing all those millions of illegal immigrants who will keep voting democrat to preserve the socialist system of the US, so beloved by the Soros clan).
... having already surpassed total US defense spending and soon to surpass total health spending and, finally all social security spending, the largest spending category of all, which means that US debt will now rise exponentially higher until the inevitable moment when the US dollar loses its reserve status and it all comes crashing down.
We conclude with another observation by CNBC's Brian Sullivan, who quotes an email by a DC strategist...
.. which lays out the proposed Biden budget as follows:
The budget deficit will growth another $16 TRILLION over next 10 years. Thats *with* the proposed massive tax hikes.
Without them the deficit will grow $19 trillion.
That's why you will hear the "deficit is being reduced by $3 trillion" over the decade.
No family budget or business could exist with this kind of math.
Of course, in the long run, neither can the US... and since neither party will ever cut the spending which everyone by now is so addicted to, the best anyone can do is start planning for the endgame.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
